
GRAIL Inc (GRAL) Stock Forecast & Price Target
GRAIL Inc (GRAL) Analyst Ratings
Bulls say
GRAIL is a leader in the multi-cancer early detection market, with their innovative blood test having the potential to detect all types of cancer at all stages. Despite a strong Q1 performance and positive expectations for upcoming catalysts such as ASCO data and FDA approval, ASP compression and uncertainties around Medicare reimbursement present potential risks. However, with a favorable risk/reward profile and a strong potential for future growth, GRAIL remains a buy rated stock.
Bears say
GRAIL is a company focused on multi-cancer early detection, which may be a strong concept, but its shares hold a neutral outlook, with a projected 2027 revenue of 40.6M diluted shares and only targeting 450 major health systems for adoption. Additionally, its lack of seamless EMR integration and reliance on the consumer self-pay market until FDA approval may pose challenges in the clinic and hinder its growth potential.
This aggregate rating is based on analysts' research of GRAIL Inc and is not a guaranteed prediction by Public.com or investment advice.
GRAIL Inc (GRAL) Analyst Forecast & Price Prediction
Start investing in GRAIL Inc (GRAL)
Order type
Buy in
Order amount
Est. shares
0 shares